Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YA1B
|
|||
| Drug Name |
Flotetuzumab
|
|||
| Indication | Acute biphenotypic leukaemia [ICD-11: 2B33.4] | Phase 2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [3], [4] | ||
| Company |
MacroGenics Rockville, MD
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 3 receptor alpha (IL3RA) | Target Info | . | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Apoptosis | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL3 Signaling Pathway | ||||
| Pathway Interaction Database | IL3-mediated signaling events | |||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-3 Signaling Pathway | |||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03739606) Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.